

PCR-/NAT *Helicobacter pylori*
(RV 533) Mai / Juni 2018



Tabelle 1: Probenzusammensetzung und erwartetes Ergebnis.

Sample composition and expected results.

	<i>Erwartet / expected</i>		<i>Probenzusammensetzung / Sample composition</i>
1815331	++	61/72	<i>Helicobacter pylori</i> (~ 5x10 ⁴ CFU/mL) Clarithromycin susceptible (wildtype 23S rDNA sequence)
1815332	∅	62	<i>Escherichia coli</i> K12
1815333	++	61/71	<i>Helicobacter pylori</i> (~ 5x10 ⁴ CFU/mL) Clarithromycin resistant (GGA mut. in 23S rDNA)
1815334	∅	62	<i>Campylobacter jejuni</i> (~ 5x10 ⁴ CFU/mL)

Tabelle 2: Häufigkeit der Mitteilung verschiedener Befunde.

Absolute numbers of reported individual results.

<i>n = 53</i>	<i>Probennummer (Sample no.)</i>				<i>Inhibition</i>				
	1815331	1815332	1815333	1815334	1815331	1815332	1815333	1815334	
Befund <i>Result</i>									
Positiv	52 ¹⁾	1	52 ¹⁾	2	n.d.	1	1	1	1
Negativ	1	52	1	51	nein <i>no</i>	52	52	52	52
Fraglich <i>Questionable</i>	0	0	0	0	ja <i>yes</i>	0	0	0	0

Tabelle 3: Häufigkeit richtig positiver und richtig negativer NAT-Befunde bei Anwendern verschiedener Methoden.

Absolute numbers and relative frequency of reported true positive and true negative results among various NAT methods.

NAT-Methode [Code] (total number *)	NAT richtig positiv <i>True positive results</i>			NAT richtig negativ <i>True negative results</i>		
	Absolut <i>Absolute</i>	Relativ <i>Relative</i>	%	Absolut <i>Absolute</i>	Relativ <i>Relative</i>	%
Hain GenoType Helico [20] (n = 25)	50	50 / 50	100	49	49 / 50	98
Ingenetix ClariRes [21] (n = 2)	4	4 / 4	100	4	4 / 4	100
r-Biopharm RIDAGENE [22] (n = 6)	12	12 / 12	100	12	12 / 12	100
Commercial assay [27] (n = 4)	8	8 / 8	100	7	7 / 8	88
In house PCR assay [28] (n = 18)	34	34 / 36	94	35	35 / 36	97
Andere / k.A. / other [29] (n = 1)	2	2 / 2	100	2	2 / 2	100

* Durch Mehrfachnennung oder fehlende Angabe kann die absolute Zahl der Ergebnisse (Tab. 2) von der Anzahl der Teilnehmer abweichen.
Due to reporting results of multiple assay systems or missing specifications, the effective numbers are not correlating with the number of participants

Comments: ¹⁾ Forty-seven of the 53 participants reported results for molecular Clarithromycin-susceptibility testing. . With the exception of 3 laboratories, all reported results were correct.